{"id":3070,"date":"2026-05-18T19:58:19","date_gmt":"2026-05-18T16:58:19","guid":{"rendered":"https:\/\/ars-patent.com\/de\/?p=3070"},"modified":"2026-05-18T20:02:04","modified_gmt":"2026-05-18T17:02:04","slug":"a-new-post-by-kirill-osipov-in-the-kluwer-patent-blog","status":"publish","type":"post","link":"https:\/\/ars-patent.com\/de\/a-new-post-by-kirill-osipov-in-the-kluwer-patent-blog\/","title":{"rendered":"A new post by Kirill Osipov in the Kluwer Patent Blog"},"content":{"rendered":"<p>Kluwer Patent Blog, an international web source dedicated to patent law, published a new post by <a href=\"https:\/\/ars-patent.com\/de\/our-team\/kirill-osipov\/\" target=\"_blank\" rel=\"noopener\">Kirill Osipov<\/a>, the Head of Legal Department at ARS-Patent. The article is a continuation of <a href=\"https:\/\/legalblogs.wolterskluwer.com\/patent-blog\/russia-the-osimertinib-case-shows-the-antimonopoly-services-role-in-pharma-patent-disputes\/\" target=\"_blank\" rel=\"noopener\">the previous post<\/a> from July 25, 2025, and addressed to two patent disputes involving patented medicines: osimertinib and axitinib.<\/p>\n<p>Both cases, which centre on generic products and allegations of unfair competition, were resolved by decisions of the Federal Antimonopoly Service (FAS). The axitinib case is particularly noteworthy as a landmark precedent: the decision was upheld by the Russian Supreme Court, which ruled in favor of the FAS and the originator company.<\/p>\n<p>Read the details of these cases in Kirill\u2019s post <a href=\"https:\/\/legalblogs.wolterskluwer.com\/patent-blog\/russia-the-antimonopoly-services-role-in-pharma-patent-disputes-part-ii\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kluwer Patent Blog, an international web source dedicated to patent law, published a new post by Kirill Osipov, the Head of Legal Department at ARS-Patent. The article is a continuation of the previous post from July 25, 2025, and addressed to two patent disputes involving patented medicines: osimertinib and axitinib. Both cases, which centre on [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19],"tags":[],"post-type":[12],"class_list":["post-3070","post","type-post","status-publish","format-standard","hentry","category-news-and-events","post-type-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/posts\/3070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/comments?post=3070"}],"version-history":[{"count":2,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/posts\/3070\/revisions"}],"predecessor-version":[{"id":3072,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/posts\/3070\/revisions\/3072"}],"wp:attachment":[{"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/media?parent=3070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/categories?post=3070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/tags?post=3070"},{"taxonomy":"post-type","embeddable":true,"href":"https:\/\/ars-patent.com\/de\/wp-json\/wp\/v2\/post-type?post=3070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}